Literature DB >> 12818824

Severe acute respiratory syndrome: avoiding the spread of infection in a radiology department.

A D King1, A S C Ching, P L Chan, A Y H Cheng, P K Wong, S S Y Ho, J F Griffith, D J Lyon, K S C Fung, P Choi, C K Li, A F B Cheng, A T Ahuja.   

Abstract

Entities:  

Mesh:

Year:  2003        PMID: 12818824     DOI: 10.2214/ajr.181.1.1810025

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


× No keyword cloud information.
  5 in total

Review 1.  Infection Control and Management Strategy for COVID-19 in the Radiology Department: Focusing on Experiences from China.

Authors:  Qian Chen; Zi Yue Zu; Meng Di Jiang; Lingquan Lu; Guang Ming Lu; Long Jiang Zhang
Journal:  Korean J Radiol       Date:  2020-07       Impact factor: 3.500

Review 2.  A Concise Review and Required Precautions for COVID-19 Outbreak in Diagnostic and Interventional Radiology.

Authors:  Ali Kord; Behnam Rabiee; Siwen Wang; Sara Rostami; Ron C Gaba; Karen L Xie
Journal:  Radiol Res Pract       Date:  2020-07-22

3.  Severe acute respiratory syndrome (SARS) in intensive care units (ICUs): limiting the risk to healthcare workers.

Authors:  J W Tang; R C W Chan
Journal:  Curr Anaesth Crit Care       Date:  2004-06-26

4.  Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious Disease.

Authors:  Philippe Brouqui; Vincenzo Puro; Francesco M Fusco; Barbara Bannister; Stephan Schilling; Per Follin; René Gottschalk; Robert Hemmer; Helena C Maltezou; Kristi Ott; Renaat Peleman; Christian Perronne; Gerard Sheehan; Heli Siikamäki; Peter Skinhoj; Giuseppe Ippolito
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

Review 5.  Is your interventional radiology service ready for SARS?: The Singapore experience.

Authors:  Te-Neng Lau; Ngee Teo; Kiang-Hiong Tay; Ling-Ling Chan; Daniel Wong; Winston E H Lim; Bien-Soo Tan
Journal:  Cardiovasc Intervent Radiol       Date:  2003 Sep-Oct       Impact factor: 2.740

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.